Real-world insights into the challenges of integrating CDK4/6 inhibitors for patients with HR+/HER2- advanced or metastatic breast cancer were garnered during a quality improvement initiative conducted at two large oncology health systems. In this webcast, leading breast cancer experts share aggregated findings, strategies to integrate best practices for evidence-based and guideline-compliant care, and patient-centered approaches to treatment decision-making and monitoring.

Physicians completing this program will earn AMA PRA Category 1 Credit™ classified as Enduring material.

Pharmacists completing this program will earn Home Study credit in Disease State Mgmt/Drug therapy (H01).